The diagnostic and prognostic value of serum endocan in patients with cirrhotic cardiomyopathy

Rom J Intern Med. 2018 Sep 1;56(3):182-192. doi: 10.2478/rjim-2018-0007.

Abstract

Background: We aimed to determine the relationship between endocan and cirrhotic cardiomyopathy.

Materials and methods: Patients with liver cirrhosis and no heart disease were included in a prospective observational study with liver disease decompensation and death as primary outcomes.

Results: 83 cirrhotic patients were included and 32 had cirrhotic cardiomyopathy. Endocan levels were significantly lower in patients with cirrhotic cardiomyopathy (5.6 vs. 7 ng/mL, p = 0.034). Endocan correlated with severity of cirrhosis, time to decompensation or death from liver disease (OR 4.5 95% CI 1.06-31.1).

Conclusion: Endocan is a promising biomarker of severity of cirrhosis and may help in the diagnosis of cardiac dysfunction in this population.

Keywords: cirrhosis; cirrhotic cardiomyopathy; echocardiography; endocan; follow-up studies; haemodynamics; portal hypertension.

Publication types

  • Observational Study

MeSH terms

  • Aged
  • Biomarkers / blood
  • Cardiomyopathies / blood
  • Cardiomyopathies / diagnosis
  • Cardiomyopathies / etiology*
  • Cohort Studies
  • Female
  • Humans
  • Liver Cirrhosis / blood
  • Liver Cirrhosis / complications*
  • Liver Cirrhosis / diagnosis
  • Liver Cirrhosis / mortality
  • Male
  • Middle Aged
  • Neoplasm Proteins / blood*
  • Prognosis
  • Proteoglycans / blood*
  • Romania / epidemiology

Substances

  • Biomarkers
  • ESM1 protein, human
  • Neoplasm Proteins
  • Proteoglycans